Showing results (21-30 of 41) with videos related to
Sort By:
Pageof 5
JAMA Neurology|November 29, 2017
Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral SclerosisJinsy A Andrews, Lisa Meng, Sarah F Kulke, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 1, 2021
Noninvasive ventilation use by patients enrolled in VITALITY-ALSStacy A Rudnicki, Jinsy A Andrews, Amy Bian, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 14, 2019
A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosisJeremy M Shefner, Merit E Cudkowicz, Orla Hardiman, et al.Muscle & Nerve|January 19, 2026
The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALSStacy A Rudnicki, Elisa Giacomelli, Katherine Herder, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 5, 2021
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trialStacy A Rudnicki, Jinsy A Andrews, Angela Genge, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 12, 2022
MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trialPaulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 16, 2014
A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALSMichael E Bozik, Hiroshi Mitsumoto, Benjamin R Brooks, et al.Journal of Medical Economics|March 17, 2023
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALSPaulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 18, 2018
Understanding the use of NIV in ALS: results of an international ALS specialist surveyTerry D Heiman-Patterson, Merit E Cudkowicz, Mamede De Carvalho, et al.Annals of Neurology|July 14, 2020
Anticoagulation Timing in Cardioembolic Stroke and Recurrent Event RiskShadi Yaghi, Tushar Trivedi, Nils Henninger, et al.Pageof 5